TABLE 1.
Demographics and baseline characteristics
| Demographic/characteristica | Placebo | NBb |
|---|---|---|
| N = 495 | N = 1001 | |
| Age, y | 44.4 ± 11.4 | 44.3 ± 11.2 |
| Gender (% female) | 84.8 | 84.6 |
| Race (% White/Black/Other) | 84/15/2c | 83/13/3c |
| Weight, kg | 99.2 ± 15.9 | 100.3 ± 16.6 |
| BMI, kg/m2 | 36.1 ± 4.3 | 36.2 ± 4.5 |
| Hypertension, %d | 21.4 | 21.2 |
| Dyslipidemia, %e | 53.1 | 55.9 |
a
Data are mean ± SD or % of participants for the Randomized population.
b
NB group includes all participants randomized to NB32 at baseline, regardless of re-randomization status.
c
Percentages may not add up to 100 because of rounding.
d
Diagnosed at baseline with hypertension or prescribed antihypertensive concomitant medications.
e
Diagnosed at baseline with dyslipidemia, hypercholesterolemia, hypertriglyceridemia, hyperlipidemia, low HDL-cholesterol or with at least one of the following values prior to first dose of study drug: triglycerides ≥200 mg/dL, LDL-cholesterol ≥160 mg/dL, total cholesterol ≥240 mg/dL, HDL-cholesterol <40 mg/dL.